Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Research

  • 1,978 Articles
  • 0 Posts
  • ← Previous
  • 1
  • 2
  • 3
  • …
  • 197
  • 198
  • Next →
Serial vaccination establishes and refines the human CD4+ T cell memory repertoire
Yi-Hui Lai, Xi Su, Silina Awad, Asgar Ansari, Juneil Jang, Ali O. Saber, Huang-Wen Chen, Hannah Jung, Annesha Sarkar, Elizabeth M. Drapeau, Warren B. Bilker, Scott E. Hensley, Laura F. Su
Yi-Hui Lai, Xi Su, Silina Awad, Asgar Ansari, Juneil Jang, Ali O. Saber, Huang-Wen Chen, Hannah Jung, Annesha Sarkar, Elizabeth M. Drapeau, Warren B. Bilker, Scott E. Hensley, Laura F. Su
View: Text | PDF

Serial vaccination establishes and refines the human CD4+ T cell memory repertoire

  • Text
  • PDF
Abstract

CD4⁺ T cells coordinate protective immunity against pathogens. However, how human CD4⁺ T cell memory is established and evolves following primary and repeated vaccinations remain incompletely understood. Using COVID-19 mRNA vaccination as a model, we tracked 50 distinct antigen-specific populations directly ex vivo with peptide–MHC class II tetramers in eight SARS-CoV-2–naïve individuals from pre-exposure baseline through memory time points after three mRNA doses. We showed that primary vaccination established the architecture of antigen-specific memory. Initial vaccination leveraged pre-existing memory while preferentially recruiting high-avidity T cells, establishing an immunodominance hierarchy dominated by a small subset of precursors. Booster vaccination refined both the magnitude and quality of T cell memory. It increased select populations and enhanced differentiation of subdominant CD4⁺ T cells. Populations that did not become more abundant after boosting retained their polyfunctional potential. Beyond establishing memory to the ancestral spike, vaccinations recruited cross-reactive T cells and increased the breadth of CD4+ T cell memory. Collectively, these findings reveal how human T cell memory evolves through sequential immunizations to generate a functionally diverse and broadly responsive memory repertoire against future viral challenges.

Authors

Yi-Hui Lai, Xi Su, Silina Awad, Asgar Ansari, Juneil Jang, Ali O. Saber, Huang-Wen Chen, Hannah Jung, Annesha Sarkar, Elizabeth M. Drapeau, Warren B. Bilker, Scott E. Hensley, Laura F. Su

×

OSTM1 restrains B-cell lymphomagenesis by promoting PDE3B degradation and activating cAMP/PKA/CREB signaling
Muhammad Usama Tariq, Namratha Sheshadri, Jianliang Shen, Jaeyong Jung, Rongrong Li, Hassan Sajjad, Mark C. Koch, Kevin Lu, Junrong Yan, Barbara Rosati, Giuseppe Caso, Brinda Vallat, Stephen K. Burley, Jun Wang, Christina Glytsou, Yi Sun, Tong Liu, Hong Li, Suzie Chen, Jiekun Yang, Zhiyuan Shen, Richard Z. Lin, Christian S. Hinrichs, Francesco Bertoni, Y. Lynn Wang, Jean Vacher, Ping Xie, Wei-Xing Zong
Muhammad Usama Tariq, Namratha Sheshadri, Jianliang Shen, Jaeyong Jung, Rongrong Li, Hassan Sajjad, Mark C. Koch, Kevin Lu, Junrong Yan, Barbara Rosati, Giuseppe Caso, Brinda Vallat, Stephen K. Burley, Jun Wang, Christina Glytsou, Yi Sun, Tong Liu, Hong Li, Suzie Chen, Jiekun Yang, Zhiyuan Shen, Richard Z. Lin, Christian S. Hinrichs, Francesco Bertoni, Y. Lynn Wang, Jean Vacher, Ping Xie, Wei-Xing Zong
View: Text | PDF

OSTM1 restrains B-cell lymphomagenesis by promoting PDE3B degradation and activating cAMP/PKA/CREB signaling

  • Text
  • PDF
Abstract

Through a genome-wide forward CRISPR/Cas9 screen in interleukin-3 (IL3)-dependent Ba/F3 cells, we identified osteoclastogenesis-associated transmembrane protein 1 (OSTM1) as a previously unrecognized tumor suppressor. Analysis of patient datasets revealed that OSTM1 is frequently deleted or downregulated in human B-cell malignancies (BCM). In mice, Cd19-Cre-driven B cell–specific monoallelic or biallelic deletion of Ostm1 cooperated with Cdkn2a loss to drive lymphomagenesis with near-complete penetrance. Mechanistically, OSTM1 directly interacts with phosphodiesterase 3B (PDE3B) and promotes its proteasomal degradation. Because PDE3B hydrolyzes cyclic AMP (cAMP), loss of OSTM1 stabilizes PDE3B, leading to suppression of tumor-suppressive cAMP-dependent PKA/CREB signaling and promotion of oncogenic transformation. Consistent with this mechanism, PDE3B is frequently amplified or upregulated in BCM, and expression of CREB/CREBBP transcriptional targets correlates positively with OSTM1 expression but inversely with PDE3B across BCM cohorts. Importantly, silencing Pde3b reverses oncogenic transformation driven by Ostm1 loss. Together, these findings establish OSTM1 as a tumor suppressor and uncover an OSTM1/PDE3B/cAMP signaling axis that restrains B-cell lymphomagenesis and may represent a therapeutically actionable vulnerability.

Authors

Muhammad Usama Tariq, Namratha Sheshadri, Jianliang Shen, Jaeyong Jung, Rongrong Li, Hassan Sajjad, Mark C. Koch, Kevin Lu, Junrong Yan, Barbara Rosati, Giuseppe Caso, Brinda Vallat, Stephen K. Burley, Jun Wang, Christina Glytsou, Yi Sun, Tong Liu, Hong Li, Suzie Chen, Jiekun Yang, Zhiyuan Shen, Richard Z. Lin, Christian S. Hinrichs, Francesco Bertoni, Y. Lynn Wang, Jean Vacher, Ping Xie, Wei-Xing Zong

×

Targeting CGRP signaling reverses maladaptive neurogenic immunosuppression in head and neck squamous cell carcinoma models
Shaquia L. Idlett-Ali, Alexander T.H. Nguyen, Khalid N.M. Abdelazeem, Diemmy Nguyen, Nicholas A. Olimpo, Michael Knitz, Jacob Gadwa, Tyler Weiskpof, Chloe Hodgson, Harshita Kumar, David Ceja Galindo, Teddi Gray, Sidharth V. Puram, Daniel L. Miller, Ginger E. Nicol, Anthony J. Saviola, Douglas G. Osborne, Sana D. Karam
Shaquia L. Idlett-Ali, Alexander T.H. Nguyen, Khalid N.M. Abdelazeem, Diemmy Nguyen, Nicholas A. Olimpo, Michael Knitz, Jacob Gadwa, Tyler Weiskpof, Chloe Hodgson, Harshita Kumar, David Ceja Galindo, Teddi Gray, Sidharth V. Puram, Daniel L. Miller, Ginger E. Nicol, Anthony J. Saviola, Douglas G. Osborne, Sana D. Karam
View: Text | PDF

Targeting CGRP signaling reverses maladaptive neurogenic immunosuppression in head and neck squamous cell carcinoma models

  • Text
  • PDF
Abstract

Neurogenic inflammation is one component that sculpts the immune milieu of solid tumors. However, it remains unclear how the sensory-neuroimmune axis shapes the immune microenvironment in cold tumors to bolster treatment resistance. Using orthotopic head and neck squamous cell carcinoma (HNSCC) models, we demonstrate tumor growth-induced sensory hyperexcitability, and that surgical sensory signaling interruption reduced tumor growth. Genetic knockout of a key neuropeptide released by sensory neurons, calcitonin gene-related peptide (CGRP), encoded by Calca, produced eradication when paired with radioimmunotherapy. Such treatment reduced Treg infiltration and immunosuppressive function in Calca knockout mice. We also observed that high-dose psilocybin functions as a CGRP inhibitor and transiently reduces tumor growth by increasing antitumor immunity. Additionally, psilocybin increased circulating serotonin, which was partially reversed with platelet activation inhibitor, clopidogrel. We observed differential effects on CD8 and Treg functionality by psilocin in vitro. Correlational analyses in plasma from human subjects following a single-dose psilocybin corroborated these findings. Together, this work underscores the complex interaction of neurogenic inflammation and the tumor immune microenvironment, highlighting a potential therapeutic avenue for HNSCC and other solid tumors.

Authors

Shaquia L. Idlett-Ali, Alexander T.H. Nguyen, Khalid N.M. Abdelazeem, Diemmy Nguyen, Nicholas A. Olimpo, Michael Knitz, Jacob Gadwa, Tyler Weiskpof, Chloe Hodgson, Harshita Kumar, David Ceja Galindo, Teddi Gray, Sidharth V. Puram, Daniel L. Miller, Ginger E. Nicol, Anthony J. Saviola, Douglas G. Osborne, Sana D. Karam

×

CD4+ T cell anergy in transplantation tolerance requires continuous Treg-dependent control of IL-2 availability
Alexandra Cassano, Domenic Abbondanza, Ying Wang, Shuang Wu, Christine M. McIntosh, Peter Wang, Jennifer B. Allocco, Montserrat Kwan, Ricardo Mora-Cartin, Ephraim Craddock, Michael S. Andrade, Anita S. Chong, Maria L. Alegre
Alexandra Cassano, Domenic Abbondanza, Ying Wang, Shuang Wu, Christine M. McIntosh, Peter Wang, Jennifer B. Allocco, Montserrat Kwan, Ricardo Mora-Cartin, Ephraim Craddock, Michael S. Andrade, Anita S. Chong, Maria L. Alegre
View: Text | PDF

CD4+ T cell anergy in transplantation tolerance requires continuous Treg-dependent control of IL-2 availability

  • Text
  • PDF
Abstract

Donor-specific transplantation tolerance promises to free recipients from complications associated with lifelong immunosuppression. Anergy, a CD4+ conventional T cell (Tconv)-intrinsic state of long-term hypofunction, is thought to arise when T cells encounter cognate antigen in the absence of costimulation. Anti-CD154 (αCD154), an antibody that blocks T cell costimulation and is currently in clinical trials, can induce donor-specific transplantation tolerance in mice in association with anergy of Tconvs recognizing persistently expressed alloantigens. Using murine models of fully mismatched cardiac allograft tolerance or repeated alloantigen exposure, we demonstrate that αCD154 is not sufficient and regulatory T cells (Tregs) are necessary to induce and sustain αCD154-mediated alloreactive Tconv anergy. Transient depletion of Tregs disrupted the induction of αCD154-mediated Tconv anergy, and in mice with established tolerance, Treg depletion transcriptionally and functionally reinvigorated previously anergic Tconvs. Mechanistically, Treg depletion increased IL-2 availability and IL-2R signaling in Tconvs, and exogenous IL-2 could bypass Treg-mediated control to partially restore Tconv function. Thus, the state of αCD154-mediated Tconv anergy is less cell-intrinsic than previously thought and requires Tregs to limit IL-2 availability for both its induction and its continuous enforcement. Selecting immunosuppressive drugs that preserve this Treg function may be critical for achieving stable clinical transplantation tolerance.

Authors

Alexandra Cassano, Domenic Abbondanza, Ying Wang, Shuang Wu, Christine M. McIntosh, Peter Wang, Jennifer B. Allocco, Montserrat Kwan, Ricardo Mora-Cartin, Ephraim Craddock, Michael S. Andrade, Anita S. Chong, Maria L. Alegre

×

Endogenous melatonin sustains cerebral mitochondrial biogenesis via SIRT1/PGC-1α signaling and protects against mitochondria-driven neurodegeneration
Abhishek Jauhari, Sergei V. Baranov, Adam C. Monek, Tanisha Singh, Fang Li, Mary A. Pickford, Yalikun Suofu, Diane L. Carlisle, Robert M. Friedlander
Abhishek Jauhari, Sergei V. Baranov, Adam C. Monek, Tanisha Singh, Fang Li, Mary A. Pickford, Yalikun Suofu, Diane L. Carlisle, Robert M. Friedlander
View: Text | PDF

Endogenous melatonin sustains cerebral mitochondrial biogenesis via SIRT1/PGC-1α signaling and protects against mitochondria-driven neurodegeneration

  • Text
  • PDF
Abstract

Mitochondrial failure is a convergent driver of neuronal aging and neurodegeneration, yet upstream factors that link age-associated changes to mitochondrial homeostasis remain incompletely defined. Melatonin, which is synthesized within neuronal mitochondria, declines with age and is further exacerbated in several neurodegenerative disorders. Here we show that endogenous melatonin is required to maintain cerebral mitochondrial biogenesis and mitochondrial quality through the SIRT1/PGC-1α signaling axis. Across young (8-week), adult (20-week), and middle-aged (1-year) mouse brains, aging was associated with reduced SIRT1/PGC-1α, decreased mtDNA copy number, and diminished abundance of oxidative phosphorylation proteins. Human hippocampal samples from older donors similarly exhibited reduced SIRT1/PGC-1α but retained mitochondrial protein abundance while accumulating oxidatively damaged mitochondria and showing reduced LC3B, consistent with impaired mitochondrial quality control. In aralkylamine N-acetyltransferase knockout (AANAT-KO) mice, endogenous melatonin deficiency suppressed SIRT1/PGC-1α, NRF1, and TFAM in an age-dependent manner, reduced mtDNA and mitochondrial transcript abundance, lowered mitochondrial protein levels, and increased mitochondrial oxidative damage. Melatonin supplementation restored the biogenesis program, increased mtDNA and mitochondrial transcripts, and rescued respiratory chain protein abundance. Finally, mitochondrial transplantation experiments indicated that mitochondrial quality contributes to neuronal integrity. Melatonin-deficient mitochondria induced neurite degeneration in wild-type neurons, whereas wild-type mitochondria rescued neurite architecture and improved survival in melatonin-deficient neurons. Together, these findings identify endogenous melatonin as a regulator of cerebral mitochondrial biogenesis and suggest that melatonin decline contributes to mitochondrial-mediated neuritic degeneration and neuronal loss.

Authors

Abhishek Jauhari, Sergei V. Baranov, Adam C. Monek, Tanisha Singh, Fang Li, Mary A. Pickford, Yalikun Suofu, Diane L. Carlisle, Robert M. Friedlander

×

FOXA2-mediated GDF15 secretion drives metastasis and CD8+ T cell exhaustion in clear cell renal cell carcinoma
Cong Huang, Rui Rui, Heng Guo, Anbang He, Wenzhi Gao, Jian Fan, Cuijian Zhang, Yanqing Gong, Liqun Zhou, Xuesong Li, Shiming He
Cong Huang, Rui Rui, Heng Guo, Anbang He, Wenzhi Gao, Jian Fan, Cuijian Zhang, Yanqing Gong, Liqun Zhou, Xuesong Li, Shiming He
View: Text | PDF

FOXA2-mediated GDF15 secretion drives metastasis and CD8+ T cell exhaustion in clear cell renal cell carcinoma

  • Text
  • PDF
Abstract

Despite recent therapeutic advances, the prognosis of patients with metastatic clear cell renal cell carcinoma (ccRCC) remains poor, and the molecular mechanisms driving metastasis are not fully understood. Herein, we identify forkhead box transcription factor A2 (FOXA2) as a key regulator of ccRCC metastasis. FOXA2 expression is elevated in metastatic ccRCC and correlates with adverse clinical outcomes. Functional assays show that FOXA2 enhances ccRCC cell invasion and metastasis both in vitro and in vivo. Mechanistically, FOXA2 recruits the histone acetyltransferase HAT1 as a transcriptional coactivator to upregulate growth differentiation factor 15 (GDF15) expression, which in turn activates GFRAL/RET-mediated STAT3 signaling and the epithelial-to-mesenchymal transition (EMT), thereby driving metastasis through both autocrine and paracrine pathways. Moreover, tumor cell-secreted GDF15 facilitates CD8+ T cell exhaustion within the tumor microenvironment, contributing to immune evasion and resistance to anti-PD-1 therapy. Importantly, pharmacologic inhibition of this pathway using either the GDF15-neutralizing antibody ponsegromab or the RET inhibitor pralsetinib markedly impairs FOXA2-driven metastasis and synergizes with anti-PD-1 therapy. Together, our findings delineate a FOXA2–GDF15–STAT3 signaling axis that orchestrates metastatic progression and immune suppression in ccRCC and suggest promising therapeutic strategies for patients with advanced disease.

Authors

Cong Huang, Rui Rui, Heng Guo, Anbang He, Wenzhi Gao, Jian Fan, Cuijian Zhang, Yanqing Gong, Liqun Zhou, Xuesong Li, Shiming He

×

C/EBP-β-mediated upregulation of CaV1.2 calcium channel increases arterial constriction in mice with ibrutinib-associated hypertension
Ludan Zhang, Shumin Yin, Wei Hou, Dan Yang, Yiyuan Jia, Yun Liu, Yan Wang, Sirui Zhao, Xiaoyan Gao, Xiaolin Sun, Xiao Lu, Jianyong Li, Ming Chu, Xiaoqing Xiong, Huayuan Zhu, Juejin Wang
Ludan Zhang, Shumin Yin, Wei Hou, Dan Yang, Yiyuan Jia, Yun Liu, Yan Wang, Sirui Zhao, Xiaoyan Gao, Xiaolin Sun, Xiao Lu, Jianyong Li, Ming Chu, Xiaoqing Xiong, Huayuan Zhu, Juejin Wang
View: Text | PDF

C/EBP-β-mediated upregulation of CaV1.2 calcium channel increases arterial constriction in mice with ibrutinib-associated hypertension

  • Text
  • PDF
Abstract

Ibrutinib, a Bruton's tyrosine kinase inhibitor, is indicated for treating chronic lymphocytic leukemia (CLL), but hypertension is a common cardiovascular adverse event. Previous studies have linked ibrutinib to cardiac events through dysregulated intracellular calcium handling, but the mechanisms underlying ibrutinib-associated hypertension remain largely unknown. Here, we followed up 225 CLL patients receiving ibrutinib or managed with watch-and-wait strategy, and identified ibrutinib as an independent risk factor for hypertension. In mice, ibrutinib elevated arterial blood pressure (BP) without structural remodeling of small arteries, and it potentiated K+-induced vasoconstriction. In vascular smooth muscle cells (VSMCs), ibrutinib upregulated CaV1.2 channel expression and function, as evidenced by enhanced CaV1.2 currents and K+-triggered-[Ca2+]i elevation. Mechanistically, ibrutinib suppressed casein kinase 2 (CK2)-mediated HSP90β phosphorylation, and stabilized C/EBP-β, which bound to the promoter of Cacna1c gene and drove CaV1.2 transcription. Significantly, C/EBP-β knockdown attenuated ibrutinib-induced CaV1.2 hyperactivity and vasoconstriction. Collectively, these findings reveal a CK2-HSP90β-C/EBP-β-CaV1.2 signaling cascade through which ibrutinib enhances vascular Ca2+ influx and vasoconstriction, thereby elevating arterial BP. Thus, this study nominates C/EBP-β as a therapeutic target for ibrutinib-associated hypertension.

Authors

Ludan Zhang, Shumin Yin, Wei Hou, Dan Yang, Yiyuan Jia, Yun Liu, Yan Wang, Sirui Zhao, Xiaoyan Gao, Xiaolin Sun, Xiao Lu, Jianyong Li, Ming Chu, Xiaoqing Xiong, Huayuan Zhu, Juejin Wang

×

Transcriptional regulation of NK cell state by ELF4 links innate immune licensing to kidney fibrosis
Shen Li, Hailong Hu, Zachary R. Lanzar, Xiangchen Gu, Elisa Cruz-Morales, Audrey C. Bochi-Layec, Andrea Sanchez-Navarro, Jihwan Park, Rojesh Shrestha, Hongbo Liu, Aaron J. Donner, Meei-Hua Lin, Thomas A. Bell, Jeffrey H. Miner, Marco Ruella, Eric Vivier, Carrie L. Lucas, Christopher A. Hunter, Katalin Susztak
Shen Li, Hailong Hu, Zachary R. Lanzar, Xiangchen Gu, Elisa Cruz-Morales, Audrey C. Bochi-Layec, Andrea Sanchez-Navarro, Jihwan Park, Rojesh Shrestha, Hongbo Liu, Aaron J. Donner, Meei-Hua Lin, Thomas A. Bell, Jeffrey H. Miner, Marco Ruella, Eric Vivier, Carrie L. Lucas, Christopher A. Hunter, Katalin Susztak
View: Text | PDF

Transcriptional regulation of NK cell state by ELF4 links innate immune licensing to kidney fibrosis

  • Text
  • PDF
Abstract

Fibrosis is a common outcome of chronic tissue injury, yet immune regulators that are conserved across species and translatable to human disease remain poorly defined. By integrating human kidney transcriptomes with multiple murine models of kidney fibrosis, we identified the ETS transcription factor ELF4 as a conserved, immune-enriched regulator associated with disease severity. ELF4 expression was highest in natural killer (NK) cells. Genetic deletion of Elf4, including NK cell–specific ablation, attenuated experimental kidney injury, with reduced inflammation, fibrosis, and loss of renal function. Single-cell and functional analyses showed that ELF4 deficiency disrupts late-stage NK cell maturation and broadly suppresses cytotoxic and interferon-γ (IFNγ) effector programs. Mechanistically, ELF4 directly sustains STAT1 transcription, maintaining a STAT1–TBX21 program required for NK cell maturation and effector competence. Consistent with this framework, NK cell depletion, IFNγ neutralization, or antisense-mediated suppression of Elf4 phenocopied renal protection. Together, these findings identify ELF4 as a transcriptional licensing factor that links NK cell state to kidney injury and highlight innate immune programming as a potential therapeutic entry point in chronic kidney disease.

Authors

Shen Li, Hailong Hu, Zachary R. Lanzar, Xiangchen Gu, Elisa Cruz-Morales, Audrey C. Bochi-Layec, Andrea Sanchez-Navarro, Jihwan Park, Rojesh Shrestha, Hongbo Liu, Aaron J. Donner, Meei-Hua Lin, Thomas A. Bell, Jeffrey H. Miner, Marco Ruella, Eric Vivier, Carrie L. Lucas, Christopher A. Hunter, Katalin Susztak

×

Epigenetic regulation of DOT1L methyltransferase activity remodels lipid metabolism to alleviate ferroptosis-induced liver injury
Jia-ming Hu, Shuo Liu, Zheng-ze Pan, Yi-jia Gao, Wei-wei Cui, Xiao Zhuang, Rong Wang, Ya-jing Han, Jia-xing Liu, Xiang-chuang Fan, Dan-dan Song, Zi-yang Zhang, Wan-yang Sun, Zong-li Zhang, Rong-rong He, Yun-fei Xu, Wei Gu, Chang Pan, Bo Chu
Jia-ming Hu, Shuo Liu, Zheng-ze Pan, Yi-jia Gao, Wei-wei Cui, Xiao Zhuang, Rong Wang, Ya-jing Han, Jia-xing Liu, Xiang-chuang Fan, Dan-dan Song, Zi-yang Zhang, Wan-yang Sun, Zong-li Zhang, Rong-rong He, Yun-fei Xu, Wei Gu, Chang Pan, Bo Chu
View: Text | PDF

Epigenetic regulation of DOT1L methyltransferase activity remodels lipid metabolism to alleviate ferroptosis-induced liver injury

  • Text
  • PDF
Abstract

Epigenetic modifications contribute to lipid-related disorders by modulating the expression of key genes involved in lipid metabolism. Accumulating evidence suggests that lipid metabolism-mediated ferroptosis drives the progression of metabolic associated steatohepatitis (MASH) and liver injury. However, whether epigenetic mechanisms remodel lipid metabolism to regulate ferroptosis-induced liver damage remains unclear. Here, through pharmacological screening of epigenetics-related compounds and CRISPR-Cas9-based screening targeting epigenetic factors, we identified DOT1 Like Histone Lysine Methyltransferase (DOT1L) as a key sensitizer of hepatocytes to ferroptosis and subsequent liver injury, whereas inhibition of DOT1L reverses the phenomenon. DOT1L loss remodeled the phospholipid landscape by decreasing PUFA-containing phospholipids while increasing monounsaturated and lysophospholipid species. Mechanistically, DOT1L depletion reduced H3K79me1 and H3K79me2 occupancy at the PLA2G7, ALDH3B1, and PLCXD3 loci, particularly across gene-body regions, while increasing promoter-proximal accessibility and expression of these phospholipid-remodeling genes. These genes suppress ferroptosis by reducing the levels of phospholipids containing polyunsaturated fatty acids (PL-PUFAs). Furthermore, we demonstrated that AMPK phosphorylates DOT1L at Ser786, weakens its association with AF9, and suppresses H3K79 methyltransferase activity and ferroptosis sensitivity. Collectively, our findings reveal the AMPK–DOT1L–H3K79 methylation axis as a novel lipid metabolic pathway that regulates ferroptosis and maintains hepatic homeostasis, offering new therapeutic insights for ferroptosis-related liver injury.

Authors

Jia-ming Hu, Shuo Liu, Zheng-ze Pan, Yi-jia Gao, Wei-wei Cui, Xiao Zhuang, Rong Wang, Ya-jing Han, Jia-xing Liu, Xiang-chuang Fan, Dan-dan Song, Zi-yang Zhang, Wan-yang Sun, Zong-li Zhang, Rong-rong He, Yun-fei Xu, Wei Gu, Chang Pan, Bo Chu

×

ATRX loss predicts poor outcomes and sensitizes to TEAD inhibition in soft tissue sarcomas
Ryan A. Denu, Anand K. Singh, Yingda Jiang, Zhao Zheng, Davis R. Ingram, Khalida M. Wani, Rossana Lazcano, Madison P. Ginn, Kumaren Anand, Bishal K. Singh, Jackson C. Ballard, Veena Kochat, Biji Chatterjee, William Padron, Sharon M. Landers, Angela D. Bhalla, Asha S. Multani, Sharvari Dharmaiah, Prit Benny Malgulwar, Yiming Cai, Jun Yao, Heather Lin, Jason T. Huse, Haoqiang Ying, Emily Z. Keung, Wei-Lien Wang, Anthony P. Conley, Shreyaskumar Patel, Neeta Somaiah, Ahsan S. Farooqi, Alexander J. Lazar, Elise F. Nassif Haddad, Keila E. Torres, Kunal Rai
Ryan A. Denu, Anand K. Singh, Yingda Jiang, Zhao Zheng, Davis R. Ingram, Khalida M. Wani, Rossana Lazcano, Madison P. Ginn, Kumaren Anand, Bishal K. Singh, Jackson C. Ballard, Veena Kochat, Biji Chatterjee, William Padron, Sharon M. Landers, Angela D. Bhalla, Asha S. Multani, Sharvari Dharmaiah, Prit Benny Malgulwar, Yiming Cai, Jun Yao, Heather Lin, Jason T. Huse, Haoqiang Ying, Emily Z. Keung, Wei-Lien Wang, Anthony P. Conley, Shreyaskumar Patel, Neeta Somaiah, Ahsan S. Farooqi, Alexander J. Lazar, Elise F. Nassif Haddad, Keila E. Torres, Kunal Rai
View: Text | PDF

ATRX loss predicts poor outcomes and sensitizes to TEAD inhibition in soft tissue sarcomas

  • Text
  • PDF
Abstract

ATRX is one of the most frequently altered genes in sarcoma and encodes an ATP-dependent chromatin remodeler implicated in maintaining heterochromatin. However, ATRX alterations have not been leveraged for sarcoma treatment. We observed loss of ATRX protein in 14% of soft tissue leiomyosarcoma (STLMS, n =127), 53% of uterine leiomyosarcoma (ULMS, n = 95), 37% of undifferentiated pleomorphic sarcoma (UPS, n = 82), and 8% of dedifferentiated liposarcoma (DDLPS, n = 84). ATRX loss was associated with significantly worse outcomes in ULMS, UPS, and DDLPS. ATRX knockout in sarcoma cells increased proliferation in cooperation with TP53 deletion, chromatin remodeling, and enrichment of PRDM4 and NFIX transcription factor motifs. PRDM4 and NFIX knockdown in ATRX-mutant sarcoma lines resulted in reduced proliferation and invasion, suggesting an epistatic relationship. Consistent with the known and re-demonstrated functional relationship between PRMD4 and YAP1, ATRX loss activated YAP1-TEAD signaling, and ATRX-deficient cells and sarcoma xenografts were more sensitive to the TEAD inhibitors VT103 and IAG933. Overall, our results identify ATRX loss as a prognostic factor of worse outcomes, implicate the ATRX-PRDM4-YAP1-TEAD axis as an underlying mechanism, and suggest use of TEAD inhibition as a potential therapeutic strategy for ATRX-deficient sarcomas.

Authors

Ryan A. Denu, Anand K. Singh, Yingda Jiang, Zhao Zheng, Davis R. Ingram, Khalida M. Wani, Rossana Lazcano, Madison P. Ginn, Kumaren Anand, Bishal K. Singh, Jackson C. Ballard, Veena Kochat, Biji Chatterjee, William Padron, Sharon M. Landers, Angela D. Bhalla, Asha S. Multani, Sharvari Dharmaiah, Prit Benny Malgulwar, Yiming Cai, Jun Yao, Heather Lin, Jason T. Huse, Haoqiang Ying, Emily Z. Keung, Wei-Lien Wang, Anthony P. Conley, Shreyaskumar Patel, Neeta Somaiah, Ahsan S. Farooqi, Alexander J. Lazar, Elise F. Nassif Haddad, Keila E. Torres, Kunal Rai

×
  • ← Previous
  • 1
  • 2
  • 3
  • …
  • 197
  • 198
  • Next →

No posts were found with this tag.

Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts